Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Passport vs Citizenship: Legal Position Explained
- 2 FemTech in India: Transforming Women's Healthcare Through Digital Innovation
- 3 Right to Trauma Care: Transforming Emergency Healthcare in India
- 4 BRICS Indore Declaration: A Roadmap for Sustainable Agriculture and Food Security
- 5 Rising Urban Fire Disasters: A Growing Crisis amid Climate Change and Urbanisation
- 6 PCPNDT Act and the Challenge of Gender Imbalance: Supreme Court’s Observations
- 7 Solar-Integrated Transport Infrastructure: Transforming Mobility into Renewable Energy Networks
- 8 Drone Warfare: Evolving Dynamics of Modern Conflicts
- 9 Twin Climate and Energy Crises: UN Calls for Urgent Global Action
- 10 Hydropower Development in the Himalayas: Balancing Development and Ecological Sustainability
